New Melanoma Cases Each year Worldwide

%

Of Skin Cancer Related Deaths are from Melanoma

%

Patients do not respond to newer immune / target therapies

Providing a Innovative New Treatment Option for Metastatic Melanoma Skin Cancer

Melanoma cancer kills 57,000 people each year world wide, costing health services billions of dollars.

While Immuno and targeted therapies have revolutionised the management and treatment of Melanoma – A massive unmet need still remains

KLAS – Therapeutics has the potential to offer a unique solution to patients and health services to address this unmet need

At KLAS Therapeutics our mission is to revolutionise the treatment of melanoma skin cancer using our patentable KLAS technology.

  • Melanoma is the 5th most common cancer – incidence and mortality continues to grow
  • In 2020 19,300 new cases were diagnosed in the UK each year, with 325,000 new cases globally
  • Despite representing less than 5% of skin cancers, it accounts for approximately 75% of skin cancer-related death
  • 5 year survival rate at best 50% for patients diagnosed with stage IV with the introduction of Immunotherapy checkpoint inhibition

image.png

World Health Organisation – Global Cancer Observatory data Estimated Increase in Melanoma Incidence and Mortality Worldwide 2020 to 2040

Current Melanoma Treatment Options

Treatment of melanoma can be very successful if caught early, but side effects and cost are phenomenally high

Surgical Removal

Common practice, but not all tumours are accessible, large excision sites required

Disfigurement can be problematic

Targeted therapy

Only 40-50% patients are eligible
High initial response with limited durability. Very high toxicities

Immunotherapy

Used successfully as an adjuvant therapy and after surgery

Extremely expensive and vary in success rate

Clinical Trials

Surgical Removal

Common practice, but not all tumours are accessible, large excision sites required

Disfigurement can be problematic

Immunotherapy

Used successfully as an adjuvant therapy and after surgery

Extremely expensive and vary in success rate

Targeted therapy

Only 40-50% patients are eligible
High initial response with limited durability. Very high toxicities

Clinical Trials

Photodynamic therapy (PDT) for KLASPDT

 

Thanks to KLAS Therapeutics PDT therapy can be used for the first time in the fight against malignant melanoma.  Our patented technology allows PDT to target the melanoma cells with clinical studies showing 500% tumour size reduction compared to PDT alone and in vitro erradication of nearly 100% of melanoma cells.

 

Can be used as a synergistic approach with current immunotherapies meaning lower toxicity with increased tolerance.

Providing hope for the future for Melanoma Patients

 

Meet the team

Klas Therapeutics has a team consisting of expert researchers; clinicians and commercialisation consultants, including Dr Rubeta Matin, Oxford University Hospitals NHS Foundation Trust Research Lead for Skin Cancer.

Mr Justin Murphy

Chief Executive Officer

Dr Bridgeen Callan

Chief Scientific Officer

Prof John Callan

Chief Technical Officer

Dr Rubeta Matin

Chief Medical Officer

Investment Opportunities

KLAS Therapeutics is actively seeking investors who want to make a real difference in the lives of Melanoma sufferers and to become a part of a dynamic team that seeks to push the boundaries of current medical therapies.

Don’t be shy, talk to us.

We reply to everyone right away. See for yourself.

    Contact Information

    j.murphy@klastx.com

    +44(0)7801857087